- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Heart Failure
The Practical Cardiology(TM) Heart Failure clinical resource center is an information hub for the latest in heart failure and heart failure management. With a focus on heart failure with reduced and preserved ejection fraction (HFrEF and HFpEF) this page features content including articles, videos, podcasts, and clinician-authored columns on FDA approvals, studies, guideline updates, and more.
Cardiology Month in Review: November 2022
November 26, 2022
The November 2022 cardiology month in review features the top content from AHA Scientific Sessions 2022, new data related to use of direct oral anticoagulation, and an FDA warning to companies over violations of the FD&C Act.
Predictors of Medical Therapy-Induced LV Improvement in HFrEF, with Viet Le PA-C
November 09, 2022
Viet Le, PA-C, discusses a study from Intermountain Healthcare examining clinical predictors of medical therapy-induced LVEF improvement in patients with heart failure with reduced ejection fraction in real-world settings.
Don't Miss a Beat: AHA 2022
November 07, 2022
In this episode of Don't Miss a Beat, hosts Muthiah Vaduganathan, MD, MPH, and Stephen Greene, MD, are bringing you insights from the AHA 2022 Scientific Sessions. In the episode, which was recorded on day 2 of the 3-day meeting, our hosts offer listeners perspective on the EMPA-KIDNEY and the TRANSFORM-HF trial, the latter of which Greene served on as an investigator.
STRONG-HF: In-Hospital Initiation of GDMT Reduces Rehospitalization, Mortality Risk in Heart Failure Patients
November 07, 2022
Results of the STRONG-HF trial provide the first evidence from a randomized clinical trial that rapid, in-hospital initiation of guideline-directed medical therapy in heart failure can improve patient outcomes.
Empagliflozin Did Not Change Left Ventricular Structure, Function in People Without Diabetes
November 06, 2022
Over a six-month period, SGLT2 inhibition with empagliflozin did not change left ventricular structure or function compared with placebo in people without diabetes or significant heart failure.
IRONMAN: IV Iron Improves Outcomes in Heart Failure Among Iron Deficient Patients
November 05, 2022
Presented at AHA 22, results of the IRONMAN trial indicate use of intravenous iron was associated with improved outcomes among people with heart failure with reduced ejection fraction and iron deficiency.
Hospital-Based Strategy Lowers Risk of Death in Patients with Acute Heart Failure
November 05, 2022
Risk stratification in the emergency department led to a 12% lower risk of death from any cause or hospitalization for cardiovascular causes compared with usual care.
Finding the Optimal Role for Omecamtiv Mecarbil in HFrEF, with Nihar Desai, MD, MPH
November 05, 2022
Nihar Desai, MD, MPH, discusses the results of a study presented at AHA 22 examining the potential impact of omecamtiv mecarbil use on outcomes and healthcare resource utilization based on data from the GALACTIC-HF trial.
Torsemide Provides No Benefit Over Furosemide for Mortality, Hospitalization in Heart Failure
November 05, 2022
Results of the TRANSFORM-HF trial presented at AHA 22 indicate there were no significant differences in rate of all-cause mortality or hospitalization with the use of torsemide compared with furosemide in people with heart failure.
COVID-19 Donor Hearts Still Viable for Transplantation, Study Finds
October 31, 2022
An analysis of data from the United Network for Organ Sharing database, which included the first 84 COVID-19-positive heart transplants, indicates hearts from COVID-19-positive donors were still viable for transplant and not associated with increased risk of organ failure rate, risk of postoperative stroke or dialysis, and 30-day mortality.